Indonesia mining ministry proposes 18 development projects for Danantara funding
Launched earlier this year, Danantara is Indonesian President Prabowo Subianto's main vehicle to achieve his 8 per cent economic growth target by 2029 by managing all shares of state-owned enterprises and reinvesting the dividends in commercial projects.
The development and acceleration of Indonesia's domestic processing industries is among Prabowo's top economic agenda priorities.
Energy and Mineral Resources Minister
Bahlil Lahadalia
said the fund had the capacity to finance and manage the projects.
The priority projects include eight projects for the processing of minerals and coal, two which support energy security, while the rest concern energy transition and the processing of agriculture and fishery products, Bahlil said at the handover ceremony.
The government has already carried out initial studies on the proposed projects, and transferred to Danantara for further assessment and implementation.
The list of projects include oil refineries and storage facilities, a plant to produce solar panels, biofuels for jets, as well as iron and alumina smelters, ministry officials said.
Danantara, which recently secured a $10 billion credit line, will invest in the projects if they meet the fund's investment criteria, its CEO Rosan Roeslani told reporters.
"The financing can come from Danantara, state-owned enterprises...We can also even invite domestic or foreign private companies to make sure we can employ the best technology," Rosan said.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
a day ago
- Business Standard
Burger King parent shares rise 5% as Q1 loss narrows; should you buy?
Shares of Restaurant Brands Asia rose over 5 per cent on Friday after the company's June-quarter loss narrowed compared to the same period last year, as it extended its value deals. Indian Burger King operator's stock rose as much as 5.2 per cent during the day to ₹85.65 per share, the steepest intraday rise since June 19, 2024. The stock pared gains to trade 3.7 per cent higher at ₹84.4 apiece, compared to a 0.153 per cent decline in Nifty 50 as of 12:50 PM. Shares of the company snapped a two-day losing streak and currently trade at 2.5 times the average 30-day trading volume, according to Bloomberg. The counter has fallen 0.4 per cent this year, compared to a 4.4 per cent advance in the benchmark Nifty 50. Restaurant Brands Asia has a total market capitalisation of ₹4,908.38 crore. Restaurant Brands Asia Q1 results The company reported a net loss of ₹41.94 crore for the three months ended June 30, compared to a ₹49.36 crore loss a year earlier. Overall revenue from operations for Restaurant Brands Asia grew 7.9 per cent to 698 crore, as a decline in sales in Indonesia partly offset the growth in India. Same-store sales, which refer to sales from stores open for at least 12 months, grew 2.6 per cent in India, led by a growth in dine-in traffic. Its India store count grew to 519 stores sequentially, with the company adding six stores in the quarter. Westlife missed quarterly profit estimates, and KFC operator Sapphire Food swung to a loss in the first quarter due to higher costs. Analysts on Restaurant Brands Asia Q1 Restaurant Brands Asia's store additions remained slow during the quarter. However, the company plans to open 60–80 new restaurants annually in India, targeting a total of 800 outlets by Financial Year 2029, driving robust store-led growth, Motilal Oswal said. As more stores mature, increasing the contribution from new stores will also support margin recovery, the brokerage said. The Indonesian business is expected to see healthy revenue growth and margin expansion in the medium term, following the closure of non-performing outlets and a streamlined portfolio, it said. Motilal Oswal maintained a 'Buy' rating with a target price of ₹135 per share. Antique Stock Broking said that going forward, management remains focused on driving traffic-led revenue growth through menu innovation and scaling up BK Café, while also working towards improving profitability. Factoring in elevated employee costs and a one-time impact from early lease termination, the brokerage has reduced its Ebitda estimates for Financial Years 2026 and 2027 by 1 per cent each. Its 'Buy' recommendation is maintained with a revised target price of ₹105.
Time of India
a day ago
- Time of India
Healthcare costs in US to shoot up following Trump tariff on Indian goods: Industry experts
New Delhi: Healthcare costs in the US will increase following the imposition of sweeping 25 per cent tariff plus an unspecified penalty on Indian goods, experts from pharmaceuticals and medical devices industry said on Thursday. President Donald Trump on Wednesday announced the imposition of a 25 per cent tariff on all goods coming from India starting August 1, plus an unspecified penalty for buying Russian crude oil and military equipment. Profits for Indian pharmaceutical firms may decline and research and development may stagnate. However, for the medical devices sector as long as the gap between duty on China and India is over 15- 20 per cent, there are positive prospects for exports to the US, according to experts. "India isn't just a key supplier of generics to the US. We are a part of the backbone of affordable global healthcare. These duties may interrupt the smooth trade flow, inflate US drug costs, stall treatments, and put even greater pressure on American healthcare budgets," OmniActive Health Technologies Executive Chairman and MD Sanjaya Mariwala said. On the other hand, he said, "Back home, the profits for Indian pharmaceutical firms may decline, and R&D may stagnate, slowing down innovation and stalling new drug clearances." AiMeD (Association of Indian Medical Device Industry) Forum Coordinator Rajiv Nath said, "Duties impact for Indian medical devices sector has to be seen from relative competitiveness - as long as duty gap between Chinese versus Indian is over 15- 20 per cent, we have positive prospects to export to USA and even put production lines in USA." Currently Indonesia and Vietnam have lower duties by 6 per cent. So for products made there they will possibly enjoy a price competitive advantage over India, he added. Stating that clarity will come after August 12 as then duties on Chinese goods will be clear, Nath said, "They were increased to over 50 per cent but temporarily reduced to 30 per cent. If post-August duties on Chinese medical devices revert to over 50 per cent and on Indian at 25 per cent, the export prospects versus China are in our favour..." He further said, "Suffice to say that whatever is the final duty that is finally announced on medical devices, if it's at least 15-20 per cent lower than applicable duty rates by US onto China then there is a strong opportunity for Indian medical devices to increase their exports to US market, if they are able to absorb the excessive high cost of regulatory approval of USFDA for market entry and find that these costs to export are sustainable over the years." However, he said, the government of India and manufacturers will need to work to improve India's competitiveness "so that we can offset the 6 per cent disadvantage over Indonesian and Vietnam competitors". Grant Thornton Bharat Partner and Tax Controversy Management Leader Manoj Mishra pointed out that the strong language used by President Trump and ongoing investigations into drug imports mean that the risk is not over yet. "Indian pharma companies should stay prepared for possible changes, especially if sector-specific duties are introduced later. That said, these tariffs are likely to be in place only for a short period, as both countries are expected to fast-track discussions for a Bilateral Trade Agreement. A balanced and stable trade deal will be key to protecting long-term interests of the sector," he noted. Similarly, Choice Broking Equity Research Analyst- Pharma Sector, Maitri Sheth said the US remains heavily reliant on India for its pharmaceutical needs, with about 50 per cent of generic drugs sourced from India. "Given the critical nature of healthcare and already elevated healthcare costs in the US, we view the likelihood of material near-term tariffs on pharma as low," Sheth added. While the headline risk persists, the structural dependence on Indian pharma and the cost sensitivity of the US healthcare system provide a strong case against aggressive tariff action on the sector, Sheth added. Medical Technology Association of India (MTaI) Chairman Pavan Choudary said President Trump's is "troubling and seems economically shortsighted and strategically misguided".
Economic Times
2 days ago
- Economic Times
Healthcare costs in US to shoot up following Trump tariff on Indian goods: Industry experts
Agencies Representative Image New Delhi: Healthcare costs in the US will increase following the imposition of sweeping 25 per cent tariff plus an unspecified penalty on Indian goods, experts from pharmaceuticals and medical devices industry said on Thursday. President Donald Trump on Wednesday announced the imposition of a 25 per cent tariff on all goods coming from India starting August 1, plus an unspecified penalty for buying Russian crude oil and military equipment. Profits for Indian pharmaceutical firms may decline and research and development may stagnate. However, for the medical devices sector as long as the gap between duty on China and India is over 15- 20 per cent, there are positive prospects for exports to the US, according to experts. "India isn't just a key supplier of generics to the US. We are a part of the backbone of affordable global healthcare. These duties may interrupt the smooth trade flow, inflate US drug costs, stall treatments, and put even greater pressure on American healthcare budgets," OmniActive Health Technologies Executive Chairman and MD Sanjaya Mariwala said. On the other hand, he said, "Back home, the profits for Indian pharmaceutical firms may decline, and R&D may stagnate, slowing down innovation and stalling new drug clearances." AiMeD (Association of Indian Medical Device Industry) Forum Coordinator Rajiv Nath said, "Duties impact for Indian medical devices sector has to be seen from relative competitiveness - as long as duty gap between Chinese versus Indian is over 15- 20 per cent, we have positive prospects to export to USA and even put production lines in USA." Currently Indonesia and Vietnam have lower duties by 6 per cent. So for products made there they will possibly enjoy a price competitive advantage over India, he added. Stating that clarity will come after August 12 as then duties on Chinese goods will be clear, Nath said, "They were increased to over 50 per cent but temporarily reduced to 30 per cent. If post-August duties on Chinese medical devices revert to over 50 per cent and on Indian at 25 per cent, the export prospects versus China are in our favour..." He further said, "Suffice to say that whatever is the final duty that is finally announced on medical devices, if it's at least 15-20 per cent lower than applicable duty rates by US onto China then there is a strong opportunity for Indian medical devices to increase their exports to US market, if they are able to absorb the excessive high cost of regulatory approval of USFDA for market entry and find that these costs to export are sustainable over the years." However, he said, the government of India and manufacturers will need to work to improve India's competitiveness "so that we can offset the 6 per cent disadvantage over Indonesian and Vietnam competitors". Grant Thornton Bharat Partner and Tax Controversy Management Leader Manoj Mishra pointed out that the strong language used by President Trump and ongoing investigations into drug imports mean that the risk is not over yet. "Indian pharma companies should stay prepared for possible changes, especially if sector-specific duties are introduced later. That said, these tariffs are likely to be in place only for a short period, as both countries are expected to fast-track discussions for a Bilateral Trade Agreement. A balanced and stable trade deal will be key to protecting long-term interests of the sector," he noted. Similarly, Choice Broking Equity Research Analyst- Pharma Sector, Maitri Sheth said the US remains heavily reliant on India for its pharmaceutical needs, with about 50 per cent of generic drugs sourced from India. "Given the critical nature of healthcare and already elevated healthcare costs in the US, we view the likelihood of material near-term tariffs on pharma as low," Sheth added. While the headline risk persists, the structural dependence on Indian pharma and the cost sensitivity of the US healthcare system provide a strong case against aggressive tariff action on the sector, Sheth added. Medical Technology Association of India (MTaI) Chairman Pavan Choudary said President Trump's is "troubling and seems economically shortsighted and strategically misguided".
